Effects of Gonadotropin-releasing Hormone Agonists on Uterine Volume and Vasculature and on the Immunohistochemical Expression of Basic Fibroblast Growth Factor (bFGF) in Uterine Leiomyomas

Lieto, Andrea Di; Falco, Massimo De; Staibano, Stefania; Iannotti, Fausto; Scaramellino, Mariangela; Salvatore, G; Mansueto, Gelsomina; Granata, Paola; Pontillo, M.; Pollio, Fabrizio; Rosa, Gaetano De

doi:10.1097/01.pgp.0000070849.25718.73

Cited by 20 publications

(9 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, GnRH antagonists induce an immediate hypoestrogenic state resulting in maximum leiomyoma reduction within 3 weeks of treatment. 13 Anastrazole induced a significant reduction of total uterine volume that is similar to that observed with GnRH agonists 14 and antagonists. 13 In contrast to …”

Section: Discussionsupporting

confidence: 66%

The Effect of Anastrazole on Symptomatic Uterine Leiomyomata

Varelas¹,

Papanicolaou²,

Vavatsi-Christaki

et al. 2007

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 66%

The Effect of Anastrazole on Symptomatic Uterine Leiomyomata

Varelas¹,

Papanicolaou²,

Vavatsi-Christaki

et al. 2007

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

show abstract

“…Growth factor signaling pathways represent a potential target for leiomyoma treatment (115). For example, Di Lieto and colleagues (116) demonstrated that reduction of uterine volume after GnRHa treatment was associated with a reduction in the expression of FGF and vascularity of leiomyomas. In addition, Ohara and colleagues (65) found that the selective progesterone receptor modulator (SPRM) asoprisnil (J867), known to inhibit proliferation and to induce apoptosis of leiomyoma cells, also decreases expression of EGF, IGF-1, TGF-β mRNA and protein.…”

Section: Role Of Individual Growth Factors In Leiomyoma Pathobiologymentioning

confidence: 99%

Signaling Pathways in Leiomyoma: Understanding Pathobiology and Implications for Therapy

Borahay

Al-Hendy

Kılıç

et al. 2015

Mol Med

129

147

View full text Add to dashboard Cite

Uterine leiomyomas are the most common tumors of the female genital tract, affecting 50% to 70% of females by the age of 50. Despite their prevalence and enormous medical and economic impact, no effective medical treatment is currently available. This is, in part, due to the poor understanding of their underlying pathobiology. Although they are thought to start as a clonal proliferation of a single myometrial smooth muscle cell, these early cytogenetic alterations are considered insufficient for tumor development and additional complex signaling pathway alterations are crucial. These include steroids, growth factors, transforming growth factor-beta (TGF-β)/Smad; wingless-type (Wnt)/β-catenin, retinoic acid, vitamin D, and peroxisome proliferator-activated receptor γ (PPARγ). An important finding is that several of these pathways converge in a summative way. For example, mitogen-activated protein kinase (MAPK) and Akt pathways seem to act as signal integrators, incorporating input from several signaling pathways, including growth factors, estrogen and vitamin D. This underlines the multifactorial origin and complex nature of these tumors. In this review, we aim to dissect these pathways and discuss their interconnections, aberrations and role in leiomyoma pathobiology. We also aim to identify potential targets for development of novel therapeutics.

show abstract

“…17 It significantly reduces both the uterine volume and fibroid size, intraoperative blood loss, pressure, pain, and symptoms produced by distortion of adjacent organs. 18,19 In addition to this well-known effects, several studies [13][14][15]20 support the hypothesis that GnRH-a treatment is successful in preventing adhesion formation after myomectomy.…”

Section: Discussionmentioning

confidence: 90%

Pelvic Adhesion and Gonadotropin-Releasing Hormone Analogue: Effects of Triptorelin Acetate Depot on Coagulation and Fibrinolytic Activities

et al. 2012

View full text Add to dashboard Cite

The study investigated the impact of gonadotropin-releasing hormone analogue (GnRH-a) on coagulation and fibrinolytic activities and its effectiveness in the prevention of pelvic adhesion after myomectomy. Thirty-two infertile women underwent myomectomy followed by adhesion evaluation surgery with a second-look laparoscopy. Before myomectomy, 15 women were treated with triptorelin acetate for 3 months and 17 received no treatment. Plasminogen activator inhibitor (PAI), thrombin activatable fibrinolysis inhibitor (TAFI), protein C (PC), plasminogen, α2-antiplasmin were determined by enzyme-linked immunosorbent assays and the activity of coagulation factors V and VIII by coagulometric methods. Patients treated with GnRH-a showed significant decrease in PAI, TAFI, factors V, and VIII (P < .05) and increased PC (P < .05), but no significant change in plasminogen and α2-antiplasmin levels compared with control group. The incidence, extent, and severity of adhesions were significantly lower in GnRH-a-treated patients compared with control group (P < .05), suggesting a possible critical role of the GnRH-a therapy in preventing postoperative adhesion development.

show abstract

Effects of Gonadotropin-releasing Hormone Agonists on Uterine Volume and Vasculature and on the Immunohistochemical Expression of Basic Fibroblast Growth Factor (bFGF) in Uterine Leiomyomas

Cited by 20 publications

References 30 publications

The Effect of Anastrazole on Symptomatic Uterine Leiomyomata

The Effect of Anastrazole on Symptomatic Uterine Leiomyomata

Signaling Pathways in Leiomyoma: Understanding Pathobiology and Implications for Therapy

Pelvic Adhesion and Gonadotropin-Releasing Hormone Analogue: Effects of Triptorelin Acetate Depot on Coagulation and Fibrinolytic Activities

Contact Info

Product

Resources

About